Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial - Wheeler, D C; Stefánsson, B V; Jongs, N (Lancet Diabetes Endocrinol, 2021)